CDC Releases Supplement to the 2008 HIV Surveillance Report
The Centers for Disease Control and Prevention (CDC) recently released the 2009 HIV Surveillance Supplemental Report, Volume 15, Number 1: HIV/AIDS Data through December 2007. This report is a supplement to the 2008 HIV Surveillance Report, Volume 20. The report provides information on the number of people living with HIV and AIDS in the United States, broken down by state and metropolitan area. The information in this report is used by the Health Resources and Services Administration (HRSA) to calculate funding allocation amounts for the Ryan White HIV/AIDS Treatment Program.
Study Suggests HAART Increases Viremia Clearance and Immune Response to Kaposi Sarcoma Herpes Virus in HIV-Infected Men Who Have Sex With Men
“[The objective of this study was to] describe the effect of HAART on Kaposi sarcoma herpes virus (KSHV) antibody response and viremia among HIV-positive MSM. … [This was a] follow-up study of 272 HIV-positive MSM (including 22 with Kaposi sarcoma) who first initiated HAART between January 1996 and July 2004 in the Swiss HIV Cohort Study. … For each individual, two serum samples, one at HAART initiation and another 24 months later, were tested for latent and lytic KSHV antibodies using immunofluorescence assays, and for KSHV viremia using PCR. Factors associated with changes in KSHV antibody titers and viremia were evaluated. … At HAART initiation, 69.1 and 75.0% of patients were seropositive to latent and lytic KSHV antibodies, respectively. Seropositivity was associated with the presence of Kaposi sarcoma, older age, lower CD8 cell count and higher CD4/CD8 ratio. Prevalence of KSHV viremia at HAART initiation was 6.4%, being significantly higher among patients with Kaposi sarcoma (35.0%), and those with HIV viral loads 100 000 copies/ml (11.7%) or higher. At 24-month follow-up, geometric mean titers (GMTs) among KSHV seropositive patients increased and antibody seroprevalence was higher. Having Kaposi sarcoma and/or CD4 cell counts less than 50 cells/microl at HAART initiation was associated both with higher probability for antibody titers to increase (including seroconversion) and larger increases in GMTs. Only one of 17 viremic patients at HAART initiation had viremia at 24-month follow-up. … [The researchers concluded that] HAART increases KSHV-specific humoral immune response and clearance of viremia among HIV-infected MSM, consistent with the dramatic protection offered by HAART against Kaposi sarcoma.”
More information is available: